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ABSTRACT 
 
Activation of ras oncogenes is found in human cancers; overall it is observed in 15% of 
all neoplasms. The purpose of this study was to assess the extent of involvement of ras 
oncogenes in osteosarcoma. Tumor samples from a series of 49 pediatric patients 
diagnosed with osteosarcoma and treated at our institution were evaluated. Paraffin-
embedded tumor samples from diagnostic biopsies, from tumor en bloc resection tissue 
after neoadjuvant chemotherapy, and samples from metastases were examined in search 
of point mutations in H, K, and N-ras genes at codons 12 and 61 by means of 
polymerase chain reaction (PCR), slot-blotting, and radioactive labeled specific DNA 
probes. A total of 92 archival samples were studied. No point mutations activating these 
genes were found. These findings suggest that the activation by point mutations at 
codons 12 and 61 of the H, K, and N-ras genes does not play a role in the pathogenesis 
of human osteosarcoma. Since no point mutations in codons 12 and 61 were detected, it 
was not possible to establish any correlation between the ras genes and clinical or 
histologic findings. 
  
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
The ras family includes three oncogenes: K-ras derived from the Kirsten sarcoma virus, 
H-ras from Harvey sarcoma virus, and N-ras from a neuroblastoma. These genes encode 
highly related proteins of 189 amino acids generically known as p21 that are thought to 
control mechanisms of cell growth and differentiation. Mutated ras proteins have lost 
the ability to become inactivated and thus they stimulate growth or differentiation 
autonomously [1, 2]. Sequence analyses have demonstrated the presence of point 
mutations in the ras oncogenes. These point mutations have been confirmed to codons 
12, 13, and 61 in human neoplasia [3]. 
 
The ras oncogene family occupies a prominent position among the oncogenes involved 
in the pathogenesis of human cancer for several reasons: activation can be detected 
reliably and conveniently in a large number of human cancers. Single sections of 
routinely fixed and paraffin-embedded tumor biopsies are enough to provide the 
required DNA for polymerase chain reaction (PCR) and the amplified DNA can be 
tested for activating point mutations [4]. Activating ras mutations can be found in as 
many as 15-20% of unselected human tumors. The highest incidence is found in 
adenocarcinomas of the pancreas (90%), colon (50%), and lung (30%), in thyroid 
tumors (50%), and in myeloid leukemia (30%) [3]. Nevertheless, no conclusive 
evidence has been found regarding the role of ras gene mutation in osteosarcoma. Cui 
and coauthors [5] have reported the absence of mutational activation of the K-ras gene 
in codons 12 and 61 in 18 tumor samples corresponding to 18 patients. 
 
The purpose of this study was to assess the extent of involvement of mutational 
activation of the H-ras, K-ras, and N-ras genes in codons 12 and 61 in pediatric 
osteosarcoma and its possible relationship to prognosis, histopathologic features, and 
pathogenesis. 
 
 
 
STUDY DESIGN 
 
Patients 
 
Forty-nine pediatric patients diagnosed with high-grade osteosarcoma [6] treated at the 
Pediatric Oncology Unit of our institution and from whom paraffin blocks were 
available from the Department of Pathology were included in the study. Biopsies were 
performed between 1983 and 1992. The number of biopsies from each patient varied 
from 1 to 5. A total of 92 samples were analyzed. 
 
 
Pathologic Selection 
 
Hematoxylin-eosin-stained sections of each biopsy were examined microscopically to 
confirm the diagnosis and to select the sample with the greatest fraction of malignant 
cells. Bone samples were fixed with 10% buffered formalin for a maximum of 24 hours, 
and then decalcified with decalcificant solution (85% formic acid, 35% chlorhydric 
acid, and water up to final volume) during 4-7 days, washed in H2O, and finally 
included in paraffin. The decalcifying solution was changed every day. 
PCR and Probe Hybridization 
 
Tissue sections were deparaffinized as described by Rogers [7]. Primer-pair sequences 
used are as previously described [8] and synthetic oligonucleotide probes are shown in 
Table 1. 
 
These primers and probes were synthesized using an automatic DNA synthesizer 
(Applied Biosystems 391 DNA Synthesizer). PCR primers were 20mer oligonucleotides 
complementary to sequences flanking codons 12 and 61 of H-, K-, and N-ras. PCR 
DNA amplification was performed as described [9]. Briefly, 2 µl of the deparaffinized 
product were amplified in a reaction mixture in a final volume of 100 µl which 
contained 100 pmol of each primer, 2.5 units of Taq DNA polymerase (Promega), 0.4 
mM of each dNTP, 5 µl of PCR 10 x buffer (500 mM KCl, 100 mM Tris-HCl pH 9, and 
1% triton X-100), and 1.5 mM MgCl2. All the samples were covered with 2 drops of 
mineral oil and the reaction was per-formed in an automated thermocycler (Hybaid 
Thermal Cycler). Forty cycles of amplification were performed (30 sec/94°C, 1 
min/Tm-5°C, 2 min/72°C). The success of the PCR was assessed by running 20 µl of 
the product on a 1% agarose:3% NuSieve gel and visualizing the product as a 112-115 
base-pair band after staining with ethidium bromide (Fig. 1). 
 
Ten microliters of TE buffer, pH 8, were added to 10 µl of the amplified product. DNA 
was denatured by heating the sample at 95°C for 5 min. Forty microliters of SSC 20 x 
were added and then applied to a Zeta-probe nylon filter (Bio Rad) under vacuum with a 
Bio-dot-SF apparatus (Bio-Rad). Duplicate filters were prepared and the DNA was 
fixed by baking. The 19mer probes were labeled at the 5' end using y-32PdATP 
(Amersham) by means of T4 polynucleotide kinase (Boehringer) and purified through a 
Elutip-D column. Filters were prehybridized for 3 hours at 56°C in 3 M 
tetramethylammonium chloride/50 mM Tris-HCL pH 7.5/2 mM EDTA/0.3% 
SDS/denatured sonicated herring sperm (100 µg/m1)/5 x Denhardt's solution. 
Approximately 1 pmol of probe (1 x 106 cpm/ml) was then added and hybridization 
continued at the same temperature for 12 hours. Filters were washed once in 2 x SSPE 
and 0.1% SDS for 10 minutes at room temperature and then in 3 M 
tetramethylammonium chloride hybridization buffer minus carrier DNA and Denhardt's 
for 10-15 minutes at 59°C. Finally, the filters were autoradiographed at -70°C (Fuji X-
ray film) using intensifying screens. 
 
 
 
RESULTS 
 
Clinical Data 
 
A total of 92 archival samples corresponding to 49 patients were studied. Twenty 
biopsies were obtained at the time of diagnosis, 39 bone samples from en bloc resection 
after neoadjuvant chemotherapy, 22 metastasis samples (20 lung metastasis, one kidney 
metastasis, one brain metastasis), nine biopsies from local relapse, and one bone sample 
after amputation. Only one biopsy was available from 24 patients, two biopsies from 13, 
three samples from seven, four samples from four, and five samples from one patient. 
Twenty-five of the 49 patients were females and 24 were males. The age at diagnosis 
varied between 5 and 21 years (mean 13.86). The site of the primary lesion at diagnosis 
was femur 25, tibia 17, humerus three, fibula one, radius one, pelvis one, and calcaneum 
one. Forty-four patients were in stage IIB and five were in stage IIIB according to the 
Enneking classification [10]. Five patients had lung disease at diagnosis, five developed 
pulmonary metastasis during treatment, and 11 developed it after chemotherapy. 
Primary site histologic subtypes were the following: 32 osteoblastic osteosarcomas, nine 
chondroblastic osteosarcomas, six fibroblastic osteosarcomas, one telangiectasic 
osteosarcoma and one small cell osteosarcoma [12]. The degree or tumor destruction 
degree after initial treatment with preoperative chemotherapy was 25 patients with 
<90% necrosis, 19 with ≥90%, and unknown in five cases (two patients underwent limb 
amputation at other centers, and in three of them this was not evaluated) [13, 14]. 
Thirty-three patients remain alive (67.3%), 15 died (30.6%), and one was lost to follow 
up (2%). Twelve patients died of disease progression, one of sepsis due to an episode of 
severe granulocytopenia secondary to cytostatic drugs, one due to severe bilateral 
pneumothorax after surgery, and one developed a second tumor (ALL) 2 years after 
treatment. 
 
The total actuarial survival rate of the patients is 67.12 ± 8.7% at 9 years of follow-up 
and the actuarial survival rate free of disease is 58% ± 8.4% at 9 years of follow-up. 
 
 
 
Laboratory Data 
 
H-ras-12; DNA Amplification. The amplification product could be visualized in 43 
samples (46.7%). Six normal DNA controls were amplified successfully and no 
amplification was detected in negative controls. 
 
Specific Probe Hybridization. Positive signals for H-ras-12- 12 wild probe were 
observed in 43 (100%) tumoral samples with amplification, in 24/49 (49%) of the 
samples in which amplification was not observed, and in normal DNA controls. No 
signals were observed in negative controls.  
No positive signals were observed in the tumor samples for probes H-ras-12-13 and H-
ras-12-14. 
 
H-ras-61; DNA Amplification. The amplification product could be visualized in 34 
samples (37%). Six normal DNA controls were successfully amplified and no 
amplification was observed in negative controls. 
 
Specific Probe Hybridization. Positive signals for H-ras-61-15 wild probe were 
observed in 34 (100%) tumoral samples with amplification, in 13/58 (22%) of the 
samples in which amplification was not observed, and in five of six normal DNA 
controls. No signals were observed in negative controls.  
No positive signals were observed in the tumor samples for probes H-ras-61-17 and H-
ras-61-18. 
 
K-ras-12; DNA Amplification. The amplification product could be visualized in 29 
samples (31.5%). Six normal DNA controls were successfully amplified and no 
amplification was observed in negative controls. 
  
Specific Probe Hybridization. Positive signals for K-ras-12-5 wild probe were observed 
in 28/29 (97%) tumoral samples with amplification, in 10/63 (16%) of the samples in 
which amplification was not visualized, and in normal DNA controls. No signals were 
observed in negative controls.  
No positive signals were observed in the tumor samples for probes K-ras-12-6 and K-
ras-12-7. 
 
K-ras-61; DNA Amplification. The amplification product could be visualized in 26 
samples (28.6%). Four of six normal DNA controls were successfully amplified and no 
amplification was observed in negative controls. 
 
Specific Probe Hybridization. Positive signals for K-ras-61-8 wild probe were observed 
in 24/26 (92.3%) tumoral samples with amplification, in 19/65 (29%) of the samples in 
which amplification was not visualized, and in normal DNA controls. No signals were 
observed in negative controls (Fig. 2). 
No positive signals were observed in the tumor samples for probes K-ras-61-10 and K-
ras-61-11. 
 
N-ras-12; DNA Amplification. The amplification product could be visualized in 46 
samples (50%). Six normal DNA controls were successfully amplified and no 
amplification was observed in negative controls. Positive controls with known 
mutations were also amplified (Table 2). 
  
Specific Probe Hybridization. Positive signals for N-ras12-GLY wild probe were 
observed in 45/46 (98%) tumoral samples with amplification, in 39/46 (85%) of the 
samples in which amplification was not visualized, and in normal DNA controls. No 
signals were observed in negative controls (Fig. 3). 
No positive signals were observed in the tumor samples for probes N-ras-12-ARG, N-
ras-12-CYS, N-ras-12-ASP, and N-ras-12-VAL. Sample 12 D had positive signals with 
probes N-ras-12-SER and N-12-ras-ALA. This sample was sequenced, the sequence 
being normal. Samples TH-p1 and p33A with known mutations used as positive 
controls gave positive signals for probe N-ras-12-ASP (Fig. 4). 
 
N-ras-61; DNA Amplification. The amplification product could be visualized in 21 
samples (22.8%). Six normal DNA controls were successfully amplified and no 
amplification was observed in negative controls. 
 
 
Specific Probe Hybridization 
 
Positive signals for N-ras-61-1 wild probe were observed in 17/21 (81%) tumoral 
samples with amplification, in 10/71 (14%) of the samples in which amplification was 
not visualized, and in normal DNA controls. No signals were observed in negative 
controls. 
No positive signals were observed in the tumor samples for probes N-ras-61-2, N-ras-
61-3, and N-ras-61-4. 
 
 
 
 
DISCUSSION 
 
The main goal of this study was to assess comprehensively the frequency of activating 
ras mutations in pediatric osteosarcoma. There was a sufficient number of cases studied 
and they fairly represent the histologic subtypes with different biologic behavior. The 
approach we used, involving PCR-oligonucleotide hybridization analysis, allows the 
screening of many cases and, with nucleotide sequence analysis, provides qualitative 
data on the type of mutation in positive cases as well as conclusive identification of the 
negative ones. 
 
Although it has been reported that fixation in 10% buffered formalin for 48 hours or less 
does not affect the efficiency of amplification, we did not achieve amplification in many 
of the samples (from 21/92 successful amplifications in codon N-61 to 46/92 successful 
amplifications in codon N-12). This low yield is probably due to three main reasons. In 
the first place, this may be attributed to formaldehyde fixation. Formaldehyde, as a 10% 
aqueous solution, is the most commonly used fixative in routine histopathologic 
practice. It is a non-coagulative fixative that acts by forming cross-links between protein 
molecules. This cross-linking of proteins forms a gel, maintaining the in vivo 
relationship of intracellular components. However, formalin is not a good fixative of 
DNA. At temperatures usually used for fixation (room temperature) no uncoiling of 
DNA occurs. The poor fixation of DNA by formalin at room temperatures causes loss 
of DNA into the fixative solution by leaching [15]. In the second place, the severe 
decalcification protocol of bone samples in strong acids for more than 4 days could also 
affect the quality of the DNA in the tumor samples. The last but probably most 
important reason for the low yield in the amplification reactions was the high degree of 
tumor necrosis in most of the samples induced by intra-arterial chemotherapy with 
cisplatinum. Twenty-five of the forty-nine patients had ≥ 90% necrosis after tumor en 
bloc resection. Nineteen had ≤ 90% necrosis (all of them had a necrosis of 60-90%), and 
unknown in five cases. 
 
Nevertheless, even if the amplification product was not visualized on agarose-NuSieve 
gels, many samples had positive signals on specific probe hybridization. We 
successfully analyzed 72 samples for codon H-12, 47 for codon H-61, 41 for codon K-
12, 47 for codon K-61, 91 for codon N-12, and 31 for codon N-61-ras. Point mutations 
were not found in any of these codons. These findings suggest that the activation by 
point mutations at codons 12 and 61 of the H, K, and N-ras genes does not play a role in 
the pathogenesis of human osteosarcoma. This is consistent with a previous report 
which only analyzed the K-ras gene at codons 12 and 61 in 18 samples [5]. Since no 
point mutations of ras genes were detected, it is not possible to establish any correlation 
between the ras genes and clinical or histologic findings. 
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Table 1. DNA probes used for the detection of point mutations 
N-ras-12 GLY wild 5'-GTT-GGA-GCA-GGT-GGT-GGT-G-3' 
N-12-SER aGT 
N-12-ARG cGT 
N-12-CYS tGT 
N-12-ALA GcT 
N-12-VAL GtT 
 
N-ras-61-1 wild 5'-ACA-GCT-GGA-CAA-GAA-GAG-T-3' 
N-61-2 nAA 
N-61-3 CnA 
N-61-4 CAn 
 
K-ras-12-5 wild 5'-GGT-GGA-GCT-GGT-GGC-GTA-G-3' 
K-12-6 nGT 
K-12-7 GnT 
 
K-ras-61-8 wild 5-ACA-GCA-GGT-CAA-GAG-GAG-G-3' 
K-61-9 nAA 
K-61-10 CnA 
K-61-11 CAn 
 
H-ras-12-12 wild 5'-GTG-GGC-GCC-GGC-GGT-GTG-G-3' 
H-12-13 nGC 
H-12-14 GnC 
 
H-ras-61-15 wild 5'-ACC-GCC-GGC-CAG-GAG-GAG-T-3' 
H-61-16 CAn 
H-61-17 nAG 
H-61-18 CnG 
 
 
 
 
Table 2. DNA controls with known mutations 
Sample DNA concentration Mutation 
Cell line THP-1 140 µ/ml GGT > GAT (Asp) N-ros pos. 12 
Patient 14A 560 µ/ml GGT > GAT (Asp) N-ros pos. 13 
Patient 20A 150 µ/ml GGT > CGT (Asp) N-ros pos. 13 
Patient 33A 390 µ/ml GGT > GAT (Asp) N-ros pos. 12 
 
